128 related articles for article (PubMed ID: 8235308)
21. In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells.
Gabor F; Wollmann K; Theyer G; Haberl I; Hamilton G
Anticancer Res; 1994; 14(5A):1943-50. PubMed ID: 7847832
[TBL] [Abstract][Full Text] [Related]
22. Adriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL60 cells.
Berczi A; Barabas K; Sizensky JA; Faulk WP
Arch Biochem Biophys; 1993 Jan; 300(1):356-63. PubMed ID: 8424669
[TBL] [Abstract][Full Text] [Related]
23. Correlation between growth inhibition and intranuclear doxorubicin and 4'-deoxy-4'-iododoxorubicin quantitated in living K562 cells by microspectrofluorometry.
Gigli M; Rasoanaivo TW; Millot JM; Jeannesson P; Rizzo V; Jardillier JC; Arcamone F; Manfait M
Cancer Res; 1989 Feb; 49(3):560-4. PubMed ID: 2910478
[TBL] [Abstract][Full Text] [Related]
24. Systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol-peptide-drug conjugates.
Shiose Y; Kuga H; Ohki H; Ikeda M; Yamashita F; Hashida M
Bioconjug Chem; 2009 Jan; 20(1):60-70. PubMed ID: 19090781
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of carboxymethylpullulan-peptide-doxorubicin conjugates and their properties.
Nogusa H; Yano T; Okuno S; Hamana H; Inoue K
Chem Pharm Bull (Tokyo); 1995 Nov; 43(11):1931-6. PubMed ID: 8575033
[TBL] [Abstract][Full Text] [Related]
26. Can cytotoxic activity of anthracyclines be related to DNA damage?
Nishiyama M; Horichi N; Mazouzi Z; Bungo M; Saijo N; Tapiero H
Anticancer Drug Des; 1990 Feb; 5(1):135-9. PubMed ID: 2317255
[TBL] [Abstract][Full Text] [Related]
27. Antitumor effects and toxicities of carboxymethylpullulan-peptide-doxorubicin conjugates.
Nogusa H; Yano T; Kajiki M; Gonsho A; Hamana H; Okuno S
Biol Pharm Bull; 1997 Oct; 20(10):1061-5. PubMed ID: 9353565
[TBL] [Abstract][Full Text] [Related]
28. Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albumin.
Di Stefano G; Fiume L; Baglioni M; Busi C; Chieco P; Kratz F; Mattioli A
Eur J Pharm Sci; 2007 Feb; 30(2):136-42. PubMed ID: 17218086
[TBL] [Abstract][Full Text] [Related]
29. [Intracellular distribution of bovine serum albumin-conjugated doxorubicin and multidrug resistance].
Takahashi N; Asakura T; Ohkawa K; Fukuda K; Aoki T
Gan To Kagaku Ryoho; 1997 Jan; 24(1):87-92. PubMed ID: 9020950
[TBL] [Abstract][Full Text] [Related]
30. Sensitivity of multidrug-resistant MCF-7 cells to a transferrin-doxorubicin conjugate.
Lemieux P; Pagé M
Anticancer Res; 1994; 14(2A):397-403. PubMed ID: 8017839
[TBL] [Abstract][Full Text] [Related]
31. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
[TBL] [Abstract][Full Text] [Related]
32. Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM.
Genne P; Duchamp O; Solary E; Pinard D; Belon JP; Dimanche-Boitrel MT; Chauffert B
Leukemia; 1994 Jan; 8(1):160-4. PubMed ID: 8289482
[TBL] [Abstract][Full Text] [Related]
33. Experimental treatment of malignant gliomas with human monoclonal antibody-drug conjugates.
Takahashi H; Adachi K; Yamaguchi F; Teramoto A
Anticancer Res; 1999; 19(5B):4151-5. PubMed ID: 10628367
[TBL] [Abstract][Full Text] [Related]
34. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
[TBL] [Abstract][Full Text] [Related]
35. FK506 reverses adriamycin resistance in a multidrug-resistant human leukemia cell line.
Natazuka T
Kobe J Med Sci; 1992 Dec; 38(6):347-63. PubMed ID: 1284834
[TBL] [Abstract][Full Text] [Related]
36. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.
Dreis S; Rothweiler F; Michaelis M; Cinatl J; Kreuter J; Langer K
Int J Pharm; 2007 Aug; 341(1-2):207-14. PubMed ID: 17478065
[TBL] [Abstract][Full Text] [Related]
37. Genotoxic effect of doxorubicin-transferrin conjugate on human leukemia cells.
Szwed M; Jozwiak Z
Mutat Res Genet Toxicol Environ Mutagen; 2014 Sep; 771():53-63. PubMed ID: 25308442
[TBL] [Abstract][Full Text] [Related]
38. The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells.
Shen J; Zhang W; Wu J; Zhu Y
Int J Hyperthermia; 2008 Mar; 24(2):151-9. PubMed ID: 18283591
[TBL] [Abstract][Full Text] [Related]
39. Hyperthermia-enhanced tumor accumulation and antitumor efficacy of a doxorubicin-conjugate with a novel macromolecular carrier system in mice with non-small cell lung cancer.
Oyama T; Kawamura M; Abiko T; Izumi Y; Watanabe M; Kumazawa E; Kuga H; Shiose Y; Kobayashi K
Oncol Rep; 2007 Mar; 17(3):653-9. PubMed ID: 17273747
[TBL] [Abstract][Full Text] [Related]
40. Induction of apoptosis by doxorubicin-transferrin conjugate compared to free doxorubicin in the human leukemia cell lines.
Szwed M; Laroche-Clary A; Robert J; Jozwiak Z
Chem Biol Interact; 2014 Sep; 220():140-8. PubMed ID: 24998637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
